CoChat

Immunophenotype of a Rat Model of Duchenne's Disease and Demonstration of Improved Muscle Strength After Anti-CD45RC Antibody Treatment

Open access
Ouisse, Laure-Hélène, Remy, Séverine, Lafoux, Aude, Larcher, Thibaut, Tesson, Laurent, Chenouard, Vanessa, Guillonneau, Carole, Brusselle, Lucas, Vimond, Nadège, Rouger, Karl, Péréon, Yann, Chenouard, Alexis, Gras-Le Guen, Christèle, Braudeau, Cécile, Josien, Régis, Huchet, Corinne, Anegon, Ignacio · 2019 · Frontiers in Immunology
Cited by 25

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Abstract

Abstract Duchenne muscular dystrophy (DMD) has as standard pharmacological therapy with corticoisteroids (CS) that decrease inflammation and immune responses present in patients and animal models. CS have however limited efficacy and important and numerous side effects. Therefore, there is a need for new anti-inflammatory and pro-tolerogenic treatments that could replace or decrease doses of CS. We first assessed the status of immune system of dystrophin-deficient rats ( Dmd mdx ) that closely reproduce the phenotype of DMD patients. Dmd mdx rats showed increased leukocyte infiltration in skeletal and cardiac muscles, containing mostly macrophages but also T cells, and increased expression of several cytokines. Anti-CD45RC Monoclonal antibody (Mab) treatment induced immune tolerance in models of organ transplantation and GVHD (Graft Versus Host Disease). We observed that muscles and blood of DMD patients contained T CD4 + and CD8 + expressing high levels of CD45RC high cells. Treatment of young Dmd mdx rats with anti-CD45RC MAb corrected skeletal muscle strength associated to a depletion of effectors CD45RC high T cells with no obvious side-effects. Prednisolone treatment of Dmd mdx rats similarly increased skeletal muscle strength and was also associated to a depletion of effectors CD45RC high cells but resulted in severe weight loss. Overall, Dmd mdx rats display important immune inflammatory response and thus represent a useful model to analyze new anti-inflammatory and tolerogenic treatments for DMD. As an example, a new treatment with anti-CD45RC antibodies improved muscle strength in Dmd mdx rats as prednisolone did but without side effects. Anti-CD45RC therapy could complement other therapies in DMD patients.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fimmu.2019.02131

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Cited by

See all 25

Metadata

Authors
Ouisse, L.-H., Remy, S., Lafoux, A., Larcher, T., Tesson, L., Chenouard, V., Guillonneau, C., Brusselle, L., Vimond, N., Rouger, K., Péréon, Y., Chenouard, A., Gras-Le Guen, C., Braudeau, C., Josien, R., Huchet, C., & Anegon, I.
Venue
Frontiers in Immunology
Published
2019-09-09
Volume
10
Pages
2131-2131
ISSN
1664-3224 (ISSN-L)
OpenAlex
W2969994091
Cited by
25
References
5
FWCI
1.07
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Immunophenotype of a Rat Model of Duchenne's Disease and Demonstration of Improved Muscle Strength After Anti-CD45RC Antibody Treatment. https://app.cochat.ai/papers/10.3389/fimmu.2019.02131
The paper
Ouisse, L.-H., Remy, S., Lafoux, A., Larcher, T., Tesson, L., Chenouard, V., Guillonneau, C., Brusselle, L., Vimond, N., Rouger, K., Péréon, Y., Chenouard, A., Gras-Le Guen, C., Braudeau, C., Josien, R., Huchet, C., & Anegon, I. (2019). Immunophenotype of a Rat Model of Duchenne's Disease and Demonstration of Improved Muscle Strength After Anti-CD45RC Antibody Treatment. Frontiers in Immunology. https://doi.org/10.3389/fimmu.2019.02131

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.